Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 20 de 2.178
Filtrer
3.
Pharmazie ; 77(2): 85-88, 2022 02 01.
Article de Anglais | MEDLINE | ID: mdl-35209969

RÉSUMÉ

The use of cisplatin may cause nephrotoxicity in patients. Hydration solutions supplemented with magnesium could reduce cisplatin-induced nephrotoxicity. In this study, we evaluated the preventive effect of magnesium pre-loading on cisplatin-induced nephrotoxicity in patients with esophageal cancer. We retrospectively evaluated the prevalence of, and risk factors for, nephrotoxicity in 160 patients with esophageal cancer treated with the 5-fluorouracil/cisplatin regimen from 2014 to 2016 with and without magnesium supplementation. Significant differences were observed between the magnesium and non-magnesium groups in terms of frequency of estimated creatinine clearance of grade 2 or higher that was at 4% (n = 3) and 13% (n = 10) (p = 0.027), respectively. The logistic regression analysis revealed that eCcr of grade 2 or higher was significantly associated with the non-magnesium regimen (odds ratio (OR), 4.175; 95% confidence interval (CI) = 1.061-16.430; p = 0.041) and age ≥ 65 years (OR, 13.951; 95% CI = 1.723-112.974; p = 0.014). This study suggests that 20 mEq magnesium pre-loading significantly reduces the prevalence of cisplatin-induced nephrotoxicity. Furthermore, when cisplatin is administered to individuals older than 64 years, a close observation for the onset of cisplatin-induced nephrotoxicity is crucial.


Sujet(s)
Antinéoplasiques , Tumeurs de l'oesophage , Maladies du rein , Sujet âgé , Antinéoplasiques/effets indésirables , Cisplatine/effets indésirables , Tumeurs de l'oesophage/traitement médicamenteux , Fluorouracil/effets indésirables , Humains , Maladies du rein/induit chimiquement , Magnésium/effets indésirables , Études rétrospectives
5.
ESMO Open ; 6(4): 100191, 2021 08.
Article de Anglais | MEDLINE | ID: mdl-34153652

RÉSUMÉ

BACKGROUND: The role of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) induction coupled with standard concurrent chemoradiotherapy (CRT) is unclear in unresectable, stage III, EGFR-mutant non-small-cell lung cancer (NSCLC). Therefore, a phase II trial was conducted to evaluate the efficacy and safety of gefitinib induction followed by CRT in this disease setting. PATIENTS AND METHODS: Patients with unresectable, EGFR-mutant, stage III NSCLC were administered gefitinib monotherapy (250 mg/day) for 8 weeks. Subsequently, patients without disease progression during induction therapy were administered cisplatin and docetaxel (40 mg/m2 each) on days 1, 8, 29, and 36 with concurrent radiotherapy at a total dose of 60 Gy. The primary endpoint was the 2-year overall survival (OS) rate, which was hypothesized to reach 85%, with a threshold of the lower limit of 60%. RESULTS: Twenty patients (median age: 66 years; male/female: 9/11; histology: 20 adenocarcinoma; stage IIIA/IIIB: 9/11; and exon 19/21: 10/10) were enrolled. The 2-year OS rate was 90% (90% confidence interval: 71.4% to 96.8%), indicating that this trial met the primary objective. The overall response rate and 1- and 2-year progression-free survival rates were 85.0%, 58.1%, and 36.9%, respectively. Grade ≥3 adverse events (>10%) included hepatic toxicity during the induction phase and neutropenia and febrile neutropenia in the CRT phase. Radiation pneumonitis grade ≥3 or treatment-related death did not occur. CONCLUSIONS: This is the first prospective study to demonstrate the favorable efficacy and safety of EGFR-TKI induction followed by standard CRT in EGFR-mutant, stage III NSCLC. Further confirmatory studies are needed.


Sujet(s)
Carcinome pulmonaire non à petites cellules , Tumeurs du poumon , Sujet âgé , Carcinome pulmonaire non à petites cellules/traitement médicamenteux , Carcinome pulmonaire non à petites cellules/génétique , Chimioradiothérapie/effets indésirables , Récepteurs ErbB/génétique , Femelle , Géfitinib/usage thérapeutique , Humains , Tumeurs du poumon/traitement médicamenteux , Tumeurs du poumon/génétique , Mâle , Mutation , Études prospectives
6.
Pharmazie ; 76(6): 261-265, 2021 06 01.
Article de Anglais | MEDLINE | ID: mdl-34078520

RÉSUMÉ

We hypothesized that suppression of peripheral circulation via cryotherapy may be effective in preventing paclitaxel-induced peripheral neuropathy (PIPN). Therefore, this study aimed to clarify whether self-administered cryotherapy could prevent PIPN in patients with early-stage breast cancer, using real-world data. A single-center, retrospective, observational study was conducted. Data from the electronic medical records of consecutive patients aged ≥ 20 years with early-stage breast cancer who received a regimen containing paclitaxel for 12 cycles with or without self-administered cryotherapy at the National Cancer Center Hospital from March 2018 to May 2019 were evaluated. The primary endpoint was the cumulative dose of paclitaxel until the onset of grade ≥ 2 PIPN. To compare the difference between the two groups, multivariable Cox proportional hazards models adjusted for prognostically important variables were used. Ninety Japanese patients were included in this study. The estimated incidence of grade ≥ 2 PIPN was 26.9% and 37.7% in the self-administered cryotherapy group and control group, respectively (P = 0.314). The multivariable Cox proportional hazards model showed that the self-administered cryotherapy group had a decreased risk of onset of grade ≥ 2 PIPN (hazard ratio: 0.63, 95% confidence interval: 0.25 to 1.39; P = 0.281). Sensitivity analyses using multivariable Cox proportional hazards models along with two propensity score-adjusted methods demonstrated consistent results. The findings suggest that the methods of self-administered cryotherapy may prevent PIPN and should be reinforced appropriately in clinical practice. A randomized controlled multicenter trial of self-administered cryotherapy is warranted.


Sujet(s)
Tumeurs du sein , Neuropathies périphériques , Tumeurs du sein/traitement médicamenteux , Cryothérapie , Femelle , Humains , Paclitaxel/effets indésirables , Neuropathies périphériques/induit chimiquement , Neuropathies périphériques/prévention et contrôle , Score de propension , Études rétrospectives
7.
Pharmazie ; 76(6): 266-271, 2021 06 01.
Article de Anglais | MEDLINE | ID: mdl-34078521

RÉSUMÉ

Hematological toxicities induced by pemetrexed plus platinum therapy remain a critical issue in clinical practice. We hypothesized that inhibition of the renin-angiotensin system (RAS) can ameliorate pemetrexed-induced hematological toxicities through drug-drug interactions involving organic anion transporters. Thus, this study aimed to clarify whether RAS inhibitors (RASIs) could prevent pemetrexed plus platinum-induced hematological toxicities. We retrospectively analyzed data from 305 consecutive patients with non-small cell lung cancer or malignant pleural mesothelioma who received their first cycle of a pemetrexed plus platinum regimen and were treated with or without RASIs. The primary endpoint was the incidence of severe myelosuppression after the first cycle. Propensity score (PS)-matched, PS-adjusted, and inverse probability of treatment weighting (IPTW) analyses were used. The number of patients with grade ≥3 hematological toxicities was 27 (8.9%). PS-matched analyses revealed that the concomitant use of RASIs was slightly associated with a lower risk of grade ≥3 hematological toxicities (odds ratio [OR], 0.68; 95% confidence interval [CI], 0.20-2.32; p = 0.536). Additionally, sensitivity analyses using PS-adjusted and IPTW methods demonstrated similar results (OR, 0.63; 95% CI, 0.19-2.15; p = 0.463 and OR, 0.37; 95% CI, 0.11-1.29; p = 0.117, respectively). These findings suggest that RASIs might prevent pemetrexed plus platinum-induced hematological toxicities.


Sujet(s)
Carcinome pulmonaire non à petites cellules , Tumeurs du poumon , Protocoles de polychimiothérapie antinéoplasique/effets indésirables , Carcinome pulmonaire non à petites cellules/traitement médicamenteux , Humains , Tumeurs du poumon/traitement médicamenteux , Pémétrexed/effets indésirables , Platine , Score de propension , Système rénine-angiotensine , Études rétrospectives
8.
AJNR Am J Neuroradiol ; 42(3): 479-486, 2021 03.
Article de Anglais | MEDLINE | ID: mdl-33478942

RÉSUMÉ

BACKGROUND AND PURPOSE: Oscillatory shear stress could not be directly measured in consideration of direction, although cerebrospinal fluid has repetitive movements synchronized with heartbeat. Our aim was to evaluate the important of oscillatory shear stress in the cerebral aqueduct and foramen magnum in idiopathic normal pressure hydrocephalus by comparing it with wall shear stress and the oscillatory shear index in patients with idiopathic normal pressure hydrocephalus. MATERIALS AND METHODS: By means of the 4D flow application, oscillatory shear stress, wall shear stress, and the oscillatory shear index were measured in 41 patients with idiopathic normal pressure hydrocephalus, 23 with co-occurrence of idiopathic normal pressure hydrocephalus and Alzheimer-type dementia, and 9 age-matched controls. These shear stress parameters at the cerebral aqueduct were compared with apertures and stroke volumes at the foramen of Magendie and cerebral aqueduct. RESULTS: Two wall shear stress magnitude peaks during a heartbeat were changed to periodic oscillation by converting oscillatory shear stress. The mean oscillatory shear stress amplitude and time-averaged wall shear stress values at the dorsal and ventral regions of the cerebral aqueduct in the idiopathic normal pressure hydrocephalus groups were significantly higher than those in controls. Furthermore, those at the ventral region of the cerebral aqueduct in the idiopathic normal pressure hydrocephalus group were also significantly higher than those in the co-occurrence of idiopathic normal pressure hydrocephalus with Alzheimer-type dementia group. The oscillatory shear stress amplitude at the dorsal region of the cerebral aqueduct was significantly associated with foramen of Magendie diameters, whereas it was strongly associated with the stroke volume at the upper end of the cerebral aqueduct rather than that at the foramen of Magendie. CONCLUSIONS: Oscillatory shear stress, which reflects wall shear stress vector changes better than the conventional wall shear stress magnitude and the oscillatory shear index, can be directly measured on 4D flow MR imaging. Oscillatory shear stress at the cerebral aqueduct was considerably higher in patients with idiopathic normal pressure hydrocephalus.


Sujet(s)
Maladie d'Alzheimer/complications , Aqueduc du mésencéphale/imagerie diagnostique , Hydrocéphalie chronique de l'adulte/liquide cérébrospinal , Hydrocéphalie chronique de l'adulte/imagerie diagnostique , Imagerie par résonance magnétique/méthodes , Contrainte mécanique , Sujet âgé , Liquide cérébrospinal/imagerie diagnostique , Liquide cérébrospinal/physiologie , Femelle , Humains , Mâle , Adulte d'âge moyen , Déplacement
9.
Insect Mol Biol ; 29(5): 490-497, 2020 10.
Article de Anglais | MEDLINE | ID: mdl-32681683

RÉSUMÉ

We describe a new member of the aldo-keto reductase (AKR) superfamily in the silkworm Bombyx mori. On the basis of its amino acid sequence and phylogenetic tree, this AKR belongs to the AKR1B family and has been designated as bmALD1. In the current study, recombinant bmALD1 was overexpressed, purified to homogeneity and kinetically characterized. We discovered that bmALD1 uses NADPH as a coenzyme to reduce carbonyl compounds such as DL-glyceraldehyde, glucose and 2-nonenal. No NADH-dependent activity was detected. To the best of our knowledge, bmALD1 is only the third AKR characterized in silkworm which, given its substrate specificity, could play a major role in glucose metabolism and antioxidant reactions. Our data provide an increased understanding of insect AKR function.


Sujet(s)
Aldose reductase/génétique , Bombyx/génétique , Protéines d'insecte/génétique , Aldose reductase/composition chimique , Aldose reductase/métabolisme , Séquence d'acides aminés , Animaux , Bombyx/croissance et développement , Bombyx/métabolisme , Protéines d'insecte/composition chimique , Protéines d'insecte/métabolisme , Cinétique , Larve/croissance et développement , Larve/métabolisme , Phylogenèse , Alignement de séquences , Spécificité du substrat
11.
Neoplasma ; 67(4): 898-908, 2020 Jul.
Article de Anglais | MEDLINE | ID: mdl-32241160

RÉSUMÉ

Genetic testing based on next-generation sequencing (NGS) analysis has recently been used to diagnose hereditary diseases. In this study, we explored the usefulness of our custom amplicon panel that targeted 23 genes related to hereditary tumors given in the American College of Medical Genetics and Genomics recommendations. We applied our custom NGS panel to samples from 12 patients previously diagnosed by Sanger sequencing as having the diseases or diagnosed clinically by meeting the diagnostic criteria in this study. Our gene panel not only successfully identified all variants detected by Sanger sequencing but also identified previously unrecognized variants that resulted in confirmation of the disease, or even in the revision of the diagnosis. For instance, a patient identified with an SDHD gene mutation actually had von Hippel-Lindau (VHL) syndrome, as determined by the presence of a pathogenic VHL gene variant. We also identified false-positive results that were generated by amplification of genome regions that are not intended to be investigated. In conclusion, NGS-based amplicon sequencing is a highly effective method to detect germline variants, as long as they are also carefully reviewed by manual inspection.


Sujet(s)
Séquençage nucléotidique à haut débit , Tumeurs , Dépistage génétique , Génomique , Humains , Mutation , Tumeurs/génétique
12.
Radiat Prot Dosimetry ; 184(3-4): 514-517, 2019 Oct 01.
Article de Anglais | MEDLINE | ID: mdl-31323670

RÉSUMÉ

Namie Town in Fukushima Prefecture, the majority of which was an evacuation area as a result of the effects of the Fukushima Daiichi Nuclear Power Plant accident, carried out a 'temporal stay' in September 2016 so that residents could check their houses. Therefore, in cooperation with the town authorities, the authors distributed personal dosemeters and behaviour record forms to record the personal dose equivalent rate and investigate the relationship between residents' external radiation dose and their behaviour. When the personal dose equivalent rate was calculated from the measured personal dose equivalent per hour, the median was 0.12 µSv h-1, the maximum value and the minimum value were 0.58 and 0.06 µSv h-1, respectively. Meanwhile, since personal fluctuations were observed in personal dose equivalent, grasping the relationship between residents' behaviour and exposed dose can be applied to risk communication.


Sujet(s)
Polluants atmosphériques radioactifs/analyse , Accident nucléaire de Fukushima , Exposition par inhalation/analyse , Exposition aux rayonnements/analyse , Contrôle des radiations/méthodes , Logement , Humains , Japon , Dose de rayonnement
13.
Radiat Prot Dosimetry ; 184(3-4): 504-509, 2019 Oct 01.
Article de Anglais | MEDLINE | ID: mdl-31038686

RÉSUMÉ

Monitoring of radioactive materials has been reported in rivers and soil in Fukushima post the Fukushima Daiichi Nuclear Power Plant accident in March 2011. However, there are few reports on the influence of this event on bacteria in forest soils and rivers. Therefore, through amplicon sequencing of 16S rDNA we compared the bacterial flora in river sediment soils from Fukushima prefecture and from an area not exposed to radioactive contamination, Aomori prefecture. The bacterial composition in the Aomori prefecture soil and Fukushima soil were found to be very similar at the phylum level. However, Fukushima soil had significantly fewer Bacteroidetes than the Aomori soil (p = 0.014), while the content of Firmicutes and Latescibacteria (WS3) was significantly higher (p = 0.001, 0.013 respectively). However, no increase in the content of radioactive-resistant bacteria was observed. In future studies, it is necessary to standardise the conditions for soil collection to assess its content of radioactive substances.


Sujet(s)
Bactéries/génétique , Sédiments géologiques/analyse , ARN ribosomique 16S/génétique , Contrôle des radiations/méthodes , Rivières/composition chimique , Polluants radioactifs du sol/analyse , Polluants radioactifs de l'eau/analyse , Bactéries/classification , Accident nucléaire de Fukushima , Centrales nucléaires
14.
Radiat Prot Dosimetry ; 184(3-4): 527-530, 2019 Oct 01.
Article de Anglais | MEDLINE | ID: mdl-31038712

RÉSUMÉ

The latest car-borne survey was carried out by Hirosaki University in order to grasp the local distribution of the absorbed dose rate in air after the evacuation order was lifted on Namie Town in 2017. The car-borne survey of absorbed dose rate in air was carried out on most of the roads which were accessible by car in Namie Town using a 3-in × 3-in NaI(Tl) scintillation spectrometer. The range of the absorbed dose rate in air was calculated to be 0.041-11 µGy h-1. The distribution maps of the absorbed dose rate in air were drawn based on the data obtained during the surveys in 2011, 2015 and 2017. The comparison of these absorbed dose rates in air suggests that the elevated absorbed dose rate in air in Namie Town caused by the FDNPP accident may be decreasing faster than natural decline which includes weathering effect and physical decay due to the artificial decontamination.


Sujet(s)
Polluants atmosphériques radioactifs/analyse , Accident nucléaire de Fukushima , Exposition aux rayonnements/analyse , Contrôle des radiations/méthodes , Retombées radioactives/analyse , Automobiles , Décontamination , Humains , Centrales nucléaires , Dose de rayonnement , Contrôle des radiations/instrumentation
15.
Radiat Prot Dosimetry ; 184(3-4): 482-485, 2019 Oct 01.
Article de Anglais | MEDLINE | ID: mdl-31038713

RÉSUMÉ

New minimally invasive indicators that are capable of predicting the biological effects and radiation damage to various organs and systems are urgently needed for the development of optimal treatment protocols for victims of radiation accidents. In the present study, we focused on microRNA (miRNA) that have recently emerged as biomarkers for predicting and diagnosing various pathological conditions and identified the serum miRNA signatures. All of the mice treated with lethal radiation alone strongly expressed certain serum miRNAs detectable for 24 h after radiation exposure, whereas the administration of radio-mitigative drug immediately after irradiation suppressed these miRNA expressions to the same levels as in control mice. These results suggest that serum miRNAs may reflect the degree of radiation damage and can be used to predict the radiation-mitigative information in victims of accidental radiation exposure.


Sujet(s)
Marqueurs biologiques/sang , Cellules sanguines/métabolisme , microARN/génétique , Exposition aux rayonnements/analyse , Protéines de fusion recombinantes/pharmacologie , Thrombopoïétine/pharmacologie , Animaux , Cellules sanguines/effets des médicaments et des substances chimiques , Cellules sanguines/effets des radiations , Relation dose-effet des rayonnements , Femelle , Analyse de profil d'expression de gènes , Souris , Souris de lignée C57BL , microARN/sang , microARN/effets des médicaments et des substances chimiques , microARN/effets des radiations , Récepteur Fc , Irradiation corporelle totale
17.
Orthod Craniofac Res ; 21(2): 84-89, 2018 May.
Article de Anglais | MEDLINE | ID: mdl-29493884

RÉSUMÉ

OBJECTIVES: To investigate the effect of release of experimentally introduced nasal obstruction on maxillofacial morphology and percutaneous arterial oxygen saturation (SpO2 ) in rats. MATERIALS AND METHODS: Six-week-old male Wistar rats (n = 36) were divided into a control group (n = 6) and a nasal obstruction group (n = 30). In the nasal obstruction group, the right nostril was occluded with silicon, which was subsequently removed after a given experimental period (days 7, 21, 35, 49 and 63). These animals were then divided into groups D7, D21, D35, D49 and D63 (each n = 6), according to the day at which the obstruction was released. The SpO2 was measured in rats with nasal obstruction at five experimental points. The maxillofacial morphology in rats on the first day and 63 days after the start of the experiment was evaluated by microcomputed tomography. RESULTS: The SpO2 was still lower at 2 weeks after the improvement of the nasal obstruction in the D49 group than in the control group. In addition, the height of the nasal maxillary complex of the D35, D49 and D63 groups was significantly decreased compared with the control group. CONCLUSIONS: The results of this study suggest that long-term unilateral nasal obstruction in growing rats may affect the growth of the nasomaxillary complex and reduce the SpO2 permanently. Therefore, early improvement of nasal obstruction in rats during the growth period may improve the SpO2 and cranial development and promote normal growth and development.


Sujet(s)
Os de la face/anatomopathologie , Maxillaire/anatomopathologie , Obstruction nasale/anatomopathologie , Animaux , Os de la face/imagerie diagnostique , Mâle , Maxillaire/imagerie diagnostique , Obstruction nasale/imagerie diagnostique , Oxygène/sang , Rat Wistar , Facteurs temps , Microtomographie aux rayons X
18.
Mucosal Immunol ; 11(3): 615-626, 2018 05.
Article de Anglais | MEDLINE | ID: mdl-29346348

RÉSUMÉ

Group V phospholipase A2 (Pla2g5) is a lipid-generating enzyme necessary for macrophage effector functions in pulmonary inflammation. However, the lipid mediators involved and their cellular targets have not been identified. Mice lacking Pla2g5 showed markedly reduced lung ILC2 activation and eosinophilia following repetitive Alternaria Alternata inhalation. While Pla2g5-null mice had Wt levels of immediate IL-33 release after one Alternaria dose, they failed to upregulate IL-33 in macrophages following repeated Alternaria administration. Unexpectedly, while adoptive transfer of bone marrow-derived (BM)-macrophages restored ILC2 activation and eosinophilia in Alternaria-exposed Pla2g5-null mice, exogenous IL-33 did not. Conversely, transfers of Pla2g5-null BM-macrophages reduced inflammation in Alternaria-exposed Wt mice. Mass spectrometry analysis of free fatty acids (FFAs) demonstrated significantly reduced FFAs (including linoleic acid (LA) and oleic acid (OA)) in lung and BM-macrophages lacking Pla2g5. Exogenous administration of LA or LA+OA to Wt mice sharply potentiated IL-33-induced lung eosinophilia and ILC2 expansion in vitro and in vivo. In contrast, OA potentiated IL-33-induced inflammation and ILC2 expansion in Pla2g5-null mice, but LA was inactive both in vivo and in vitro. Notably, Pla2g5-null ILC2s showed significantly reduced expression of the FFA-receptor-1 compared to Wt ILC2s. Thus, macrophage-associated Pla2g5 contributes significantly to type-2 immunity through regulation of IL-33 induction and FFA-driven ILC2 activation.


Sujet(s)
Alternaria/immunologie , Alternariose/immunologie , Granulocytes éosinophiles/immunologie , Group V Phospholipases A2/métabolisme , Poumon/immunologie , Lymphocytes/immunologie , Macrophages/immunologie , Pneumopathie infectieuse/immunologie , Transfert adoptif , Animaux , Mouvement cellulaire , Cellules cultivées , Cytokines/métabolisme , Acide gras libre/métabolisme , Group V Phospholipases A2/génétique , Interleukine-33/métabolisme , Mâle , Souris , Souris de lignée C57BL , Souris knockout , Lymphocytes auxiliaires Th2/immunologie
19.
Breast Cancer Res Treat ; 163(3): 545-554, 2017 Jun.
Article de Anglais | MEDLINE | ID: mdl-28337663

RÉSUMÉ

PURPOSE: This retrospective study evaluated the effect of clinical background and treatment line on time to treatment failure (TTF) in advanced/metastatic breast cancer (AMBC) patients receiving F500 in Japan (UMIN 000015168). METHODS: Patients who commenced F500 treatment were registered at 16 sites in Japan. Correlations between baseline clinicopathological factors, treatment line, and TTF were investigated by Kaplan-Meier analysis. TTF data were analyzed using univariate analysis and multivariate analysis with a Cox proportional hazards model. RESULTS: Data for 1072 patients were available; 1031 patients (96.2%) were evaluable for efficacy. F500 was administered as first-line treatment in 2.0%, second-line in 22.7%, third-line in 26.7%, and ≥fourth-line in 48.6% patients. Median TTF was 5.4 months. Multivariate analysis found that earlier F500 use (first and second vs. third vs. ≥fourth line; hazard ratio (HR) = 0.80, 95% confidence interval (CI) 0.74-0.86; P < 0.001), longer period from AMBC diagnosis to F500 use (≥3 vs. <3 years; HR 0.60, 95% CI 0.51-0.70; P < 0.001), and no prior palliative chemotherapy administered for unresectable or metastatic breast cancer (no vs. yes; HR 0.69, 95% CI 0.60-0.80; P < 0.001) were associated with significantly longer TTF. Among 691 patients, where information on histologic/nuclear grade was available, a low grade was also associated with a longer TTF, but this finding was not maintained among patients with recurrent breast cancer (N = 558). Among women with recurrent breast cancer, a longer DFI between a patient's initial breast cancer diagnosis and their recurrence was associated with a longer TTF on F500 therapy. CONCLUSIONS: Our study showed that treatment period of F500 was longer when used in earlier-line treatment. For patients on F500, TTF was also longer for patients who had not received prior palliative chemotherapy and for those who had a longer period from their AMBC diagnosis to F500 use.


Sujet(s)
Antinéoplasiques hormonaux/administration et posologie , Protocoles de polychimiothérapie antinéoplasique/administration et posologie , Tumeurs du sein/traitement médicamenteux , Oestradiol/analogues et dérivés , Adulte , Sujet âgé , Antinéoplasiques hormonaux/effets indésirables , Protocoles de polychimiothérapie antinéoplasique/effets indésirables , Tumeurs du sein/anatomopathologie , Survie sans rechute , Oestradiol/administration et posologie , Oestradiol/effets indésirables , Femelle , Fulvestrant , Humains , Japon , Estimation de Kaplan-Meier , Adulte d'âge moyen , Récidive tumorale locale/anatomopathologie , Stadification tumorale , Modèles des risques proportionnels , Études rétrospectives , Échec thérapeutique , Résultat thérapeutique
20.
Ultrasound Obstet Gynecol ; 50(6): 781-787, 2017 Dec.
Article de Anglais | MEDLINE | ID: mdl-27943496

RÉSUMÉ

OBJECTIVES: Cervical pregnancy (CP) is a rare type of ectopic pregnancy. While methotrexate (MTX) is generally the first-line method of choice for clinically stable women, there is still no consensus on the most appropriate treatment for this abnormal pregnancy. The aim of this study was to investigate the efficacy of a single local MTX injection under transvaginal ultrasound guidance for the initial treatment of CP and to assess post-treatment fertility. METHODS: We reviewed retrospectively 15 patients with CP treated with local MTX injection under transvaginal ultrasound guidance. In all patients, the serum human chorionic gonadotropin (hCG) levels were monitored and the gestational sac was evaluated using ultrasonography after treatment. Magnetic resonance imaging (MRI) was performed as necessary. We evaluated the patients' clinical characteristics and clinical course after treatment, the efficacy of the treatment and the post-treatment fertility in patients desiring subsequent pregnancy. RESULTS: The median estimated gestational age at the time of MTX injection was 6 + 2 (range, 5 + 2 to 11 + 0) weeks. All 15 patients were treated successfully, without the need for blood transfusion or surgical procedures; however, three patients required an additional local MTX injection due to a poor decline in serum hCG level following the initial injection, while one patient required uterine artery embolization due to persistent vaginal bleeding and an enlarging gestational sac with blood vessels visible on contrast-enhanced MRI. The mean time following initial MTX injection for hCG normalization was 43.8 (95% CI, 33.3-54.3) days and for resumption of menses was 68.4 (95% CI, 51.9-84.9) days. Seven of the 10 women desiring subsequent pregnancy following treatment had uneventful pregnancy, one became pregnant but miscarried spontaneously at 8 weeks of gestation, one was treated by laparoscopic surgery after diagnosis of a tubal pregnancy and one did not conceive. CONCLUSIONS: A single, ultrasound-guided, local MTX injection is apparently effective for the treatment of CP without the need for concomitant procedures or surgical intervention. Furthermore, this conservative technique both preserves fertility and allows for the possibility of subsequent uneventful pregnancy. Copyright © 2016 ISUOG. Published by John Wiley & Sons Ltd.


Sujet(s)
Abortifs non stéroïdiens/administration et posologie , Col de l'utérus/imagerie diagnostique , Méthotrexate/administration et posologie , Grossesse extra-utérine/imagerie diagnostique , Grossesse extra-utérine/traitement médicamenteux , Échographie interventionnelle , Adulte , Col de l'utérus/anatomopathologie , Femelle , Fécondité , Humains , Grossesse , Grossesse extra-utérine/anatomopathologie , Études rétrospectives , Résultat thérapeutique
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE
...